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Abstract
Atopic dermatitis (AD) is a widespread condition that appears to be increasing in prevalence and severity worldwide, yet 
the underlying mechanisms are not well understood. Recent research has identified various similarities between AD and 
autoimmune conditions, as well as indicating that there may be an association between AD and autoimmunity. This sys-
tematic review evaluates the association between AD and autoimmunity, as well as between severity of disease in AD and 
autoimmunity, with an emphasis on the associations with autoantibodies. MEDLINE (1946 to December 2017) and Embase 
(1974 to December 2017) databases were searched. Further relevant articles were retrieved from reference lists. Only studies 
measuring direct indicators of autoimmunity, in humans, were included. Qualitative analysis was carried out for all studies. In 
addition, quantitative analysis was used to evaluate prevalence of IgE autoantibodies and anti-nuclear antibodies (ANAs) in 
AD patients and control subjects. The Mantel–Haenszel method was used with a random-effects model. 28 studies assessed 
the occurrence of autoantibodies in AD patients and 16 studies were used to evaluate association between disease severity 
and autoantibodies. Pooled analysis from 14 studies, involving 986 AD patients and 441 control subjects, showed that IgE 
autoantibodies were significantly more prevalent in patients with AD (P < 0.00001) than control subjects. Similar analysis 
was carried out for ANAs, with eight studies that involved 1045 AD patients and 1273 control subjects. ANAs were signifi-
cantly more prevalent in patients with AD (P = 0.003). This quantitative analysis supported an association between AD and 
IgE autoantibodies, as well as between AD and ANAs. There was insufficient data to make similar conclusions for other 
indicators of autoimmunity. The weight of evidence also suggests an association between IgE autoantibodies and disease 
severity. There was insufficient evidence to make this link for other indicators of autoimmunity.
Keywords Atopic dermatitis · Autoimmunity · Autoantibody · IgE · IgG · IgA · Anti-nuclear autoantibodies
Introduction
The term Atopic Dermatitis (AD) was first used by Wise 
and Sulzberger in 1933 [1]. The World Allergy Organisa-
tion defines eczema (also known as atopic eczema dermatitis 
syndrome (AEDS) and as AD throughout this review) as 
‘an inflammatory, chronically relapsing, non-contagious and 
extremely pruritic skin disease’ [2].
Prevalence of AD worldwide is high, with 7.9% of 
6–7  years presenting with the condition in the ISAAC 
Phase 3 study [3]. AD appears to be increasing in prevalence 
globally, with centres reporting increases in self-reported 
AD and severe AD [3]. There was significant variance in the 
prevalence of AD between centres, both within and across 
regions, which has been attributed, in part, to environmen-
tal differences [4]. The increasing prevalence and sever-
ity of AD makes it essential to understand the underlying 
mechanisms of the disease, enabling more effective future 
treatments.
AD is traditionally thought of as an allergic condition 
with extrinsic allergens driving the immune response. The 
discovery of a deficiency in the stratum corneum caused 
by filaggrin gene mutations supports this, as impaired skin 
barrier function allows for allergens to infiltrate the body, 
inducing an immune response [5]. AD patients with these 
mutations are more likely to have persistent, severe, aller-
gen-driven symptoms, but some patients continue to suffer 
from AD despite removal of stimuli such as dust mites or 
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pollen [6]. Overall, as many as two-thirds of AD patients 
demonstrate ‘no measurable allergen-specific IgE antibody 
sensitization’ [7].
One hypothesis as to why chronic inflammation persists, 
despite removal of environmental allergens, is infection by 
Staphylococcus aureus. S. aureus colonization was found in 
more than 90% of patients and was found to correlate signifi-
cantly with severity [8]. S. aureus has a contribution to most 
AD lesions, both by worsening inflammation through direct 
action of toxins and by increasing production of IgE antibod-
ies [9]. It would follow that other skin based microorgan-
isms, such as the fungus Malassezia sympodialis, could also 
cause this type of exacerbation, but this does not account for 
patients that suffer AD lesions without allergic sensitisation.
Despite the traditional understanding of AD, there has 
been evidence to suggest there might be an autoimmune 
component to the disease. Disease progression in AD is 
similar to that in known autoimmune conditions, involving 
periods of relapse and remission. Furthermore, a significant 
association has been found between AD and 11 autoimmune 
conditions, as well as the fact that AD patients are more 
likely to present with ‘multiple autoimmune comorbidi-
ties’ [10]. Finally, immediate skin reactions to some human 
proteins indicate that, for some patients, IgE autoantibodies 
are produced [11] which could contribute to disease pro-
gression. Researchers have also recently claimed that they 
have proven that ‘atopic dermatitis … is an immune-driven 
(autoimmune) disease’ [12] by treating AD with Dupilumab. 
This blocked IL-4 and IL-13 [13], to prevent Th2 cytokines 
from incorrectly targeting autologous tissues.
Methods
This systematic review investigates the link between AD and 
autoimmunity (with an emphasis on autoantibodies), pro-
viding an update to, and widening of scope of, a systematic 
review from 6 years earlier [14]. The present review evalu-
ates the strength of the link between AD and autoantibodies, 
and whether there is an association between AD severity and 
autoantibodies.
Identification of relevant studies
Two modifications were made to the search strategy 
employed in 2012 by Tang et al. [14]: ‘autologous’ was 
added as a search term and the Embase database was 
searched in addition to MEDLINE. These alterations 
ensured the search strategy reflected current terminology 
and that as many relevant papers as possible were found.
The search terms were as follows:
 1. exp Dermatitis, Atopic/
 2. atopic dermatitis.mp.
 3. dermatitis atopic.mp.
 4. exp Eczema/
 5. childhood eczema.mp.
 6. infantile eczema.mp.
 7. 1 or 2 or 3 or 4 or 5 or 6
 8. exp Autoimmunity/




 13. ribosomal P2.mp.
 14. exp Thioredoxins/
 15. exp immunoglobulin G/
 16. exp immunoglobulin E/





 22. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 
18 or 19 or 20 or 21
 23. 7 and 22
 24. limit 23 to (male and female and humans and humans)
Database searching was carried out during October to 
December 2017.
The PRISMA diagram [15] in Fig. 1 gives an overview of 
the number of papers at each stage of the literature search. 
Titles and abstracts from this search were checked, yield-
ing 165 papers that warranted full-text analysis. These were 
scanned in full, with 28 studies providing evidence relating 
to an association between AD and autoantibodies, and 16 
Fig. 1  PRISMA diagram (adapted from [16])
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that evaluated severity of AD in relation with the occurrence 
of autoantibodies. During this full-text analysis, the refer-
ence sections of papers were checked to identify relevant 
papers that had not appeared in the search results. Most 
papers excluded at this point were conference proceedings 
or included results not linked to autoimmunity and AD.
Inclusion criteria
Language
All literatures evaluated in this systematic review were in 
English (including papers that had already been translated 
in to English).
Types of studies
Due to the wide range of study designs present in the litera-
ture, all the types of study were included. The main types of 
study evaluated were case–control studies, case series, and 
individual case reports.
Types of participants
This systematic review evaluated all studies involving human 
participants, irrespective of age or gender. Studies varied in 
the age ranges of the participants (details in Tables 1, 3, 4, 
5, 7): most included adults only or a mixture of children 
and adults, whereas a few studies included children only. 
However, there was no apparent effect of participants’ age 
on the relationship between autoreactivity and AD (Table 2) 
or severity of AD (Table 6). All the literature was included 
regardless of whether they had clear criteria for selecting 
patients with AD. These criteria have been noted for all 
studies in appendices, but have only been referred to in the 
main text when these criteria are unclear or missing.
Types of publication
In this systematic review, all papers published in journals 
were included, with the exception of reviews and editorials. 
Letters to journals were included, as they were a key source 
of smaller studies. Grey literature was not included.
Outcome measures
The papers evaluated in the systematic review were hetero-
geneous in both study design and outcome measures. The 
only restriction was that studies had to provide direct evi-
dence of autoantibodies. When evaluating the association 
between autoantibodies and AD, any tests that indicated 
autoantibodies, for example, ELISA and skin prick tests 
(SPTs), were included. When evaluating the association 
between severity of AD and autoantibodies, all measures 
of severity were included. The most common measures 
of severity were SCORAD (SCORing Atopic Dermatitis) 
[44] and Rajka and Langeland [45] systems, although some 
authors used other assessments of severity.
Statistical analysis
Where appropriate, a quantitative analysis was carried out 
using Review Manager 5.3 [46]. The Mantel–Haenszel 
method was used with a random-effects model to account 
for the variation in study design and resultant difference in 
effect size.
Fig. 2  Forest plot showing data from all studies into IgE antibodies. ‘Events’ are instances of autoimmunity, and ‘total’ refers to the total number 
of people in that group of a study
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Results
Association of autoantibodies with atopic 
dermatitis
28 papers were identified that fulfilled the inclusion criteria 
and were relevant to this part of the review. The main indica-
tors of autoimmunity investigated were specific IgE and IgG 
antibodies, as well as IgG ANAs.
Autoantibodies of IgE class
14  studies investigated the presence of specific IgE 
autoantibodies in patients with AD; the details of these 
studies are summarised in Table 1 (in alphabetical order 
of the first authors). Twelve were case–control studies, of 
which 11 indicated that certain IgE autoantibodies were 
significantly more common in patients with AD. The study 
quality was generally good, with well-described protocols, 
often using western blot, ELISA or SPT techniques, and 
robustly defined criteria for selection of AD patients in 
most cases. Most studies evaluated the presence of IgE 
autoantigens to epithelial cells, epithelial cell extracts, 
and other proposed autoantigens associated with the skin. 
Furthermore, the control groups were comprised predom-
inantly of healthy individuals which makes comparison 
between, and pooling of, individual studies much easier 
and more useful. This meant an analysis could be car-
ried out on the combined data, which established an odds 
ratio of 12.97 (with 95% confidence limits of 5.14–32.68) 
and P < 0.00001, indicating that IgE autoantibodies are 
significantly more likely to be identified in patients with 
AD compared to the control groups (Fig. 2). This effect 
seemed to be uniform across all tested antigens, although 
the majority of evidence concerns specific antibodies to 
epithelial cell extracts. A qualitative analysis of the stud-
ies also indicated that all but one (13/14) concluded that 
Table 2  Association of 
autoantibodies with atopic 
dermatitis
*Differences were statistically significant
†Differences were not statistically significant
§ Autoreactivity was significantly lower in AD patients
Marker of autoimmunity Papers that indicate autoreactivity is 
more common in patients with AD
Papers that do not indicate autoreactiv-





Hiragun et al. (for QRX) [20]
Ilves, Virolainen and Harvima [21]*
Kortekangas-Savolainen et al. [23]







Hiragun et al. (for rMGL_1304) [20]†
Kawamoto et al. [22]§
IgG autoantibodies 4








Du Toit et al. [16]
El-Rachkidy et al. [36]
Kawamoto et al. [22]
(for 5 peptides)**, (for 3 peptides)§
IgA autoantibodies 0 1
Ress et al. [37]
ANAs 7
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IgE class autoantibodies are more common in AD patients 
than controls (Table 2).
Autoantibodies of IgG class
Eight studies investigated the presence of specific IgG 
autoantibodies in AD (Table 3). However, it was not 
possible to carry out a quantitative analysis: whilst the 
studies predominantly used ELISA techniques, the study 
design was too varied for a pooled analysis. Some studies 
only compared AD patients against patients with other 
conditions, for example psoriasis, whilst others only pro-
vided mean titres. Furthermore, only three of the studies 
had clear definitions for AD diagnosis. Because of the 
more variable study design, it was more appropriate to 
carry out a qualitative review. Levels of IgG autoanti-
bodies specific to  SART2161,  SART2899,  ART413 [22], 
CCL3 [31] and CD28 [32], as well as APL antibodies 
[34] were significantly higher than in their respective 
control groups, but levels of autoantibodies specific to 
β2GPI [35], TNF-α, IFN-α, CCL-5, CCL-2, IL-17 [31], 
and five other peptides [22] were not significantly higher. 
Autoantibodies against DFS70 [33] and  FcεR1α autoan-
tibodies [16] were more commonly identified in AD 
patients than the respective control groups, but no statis-
tical analysis was carried out. Finally, AD patients were 
found not to display an autoreactive response to stratum 
corneum antigens, but psoriasis patients did (although 
no statistical analysis was carried out). Overall, there is 
no clear picture as to the presence of IgG autoantibodies 
in AD patients (Table 2). The mixed results, combined 
with more variable study techniques and less clarity with 
respect to inclusion criteria, means that more research 
is required into the relationship between AD and IgG 
autoantibodies.
Autoantibodies of IgA class
Only one study solely investigated IgA autoantibodies in 
AD: Ress et al. [37] carried out a large case–control study, 
comprising 297 patients with AD and 52 healthy control 
subjects. ELISA techniques were used to determine the 
presence of IgA-anti-transglutaminase 1 (anti-TG1) and 
IgA-anti-transglutaminase 3 (anti-TG3) in the control 
group and AD group. However, this study did not indi-
cate an association between IgA autoantibodies and AD 
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Anti‑nuclear autoantibodies
Eight studies investigated ANAs in AD (Table 4), with 
two of these including ANAs as part of a wider study. 
Six of the eight were case–control studies. Most of these 
papers applied clear, commonly used definitions of AD 
and most used well-described methods—particularly indi-
rect immunofluorescence—to identify ANAs. Seven of 
the eight papers indicate that ANAs occurred more com-
monly in patients with AD than in the control subjects 
(Table 2). Furthermore, the pooling of data showed that 
patients with AD have a significantly higher frequency 
of ANAs than the control subjects with an odds ratio of 
2.18 (95% confidence intervals 1.31–3.64) and P = 0.003 
(Fig. 3).
Association of autoantibodies with severity 
of atopic dermatitis
The second part of this systematic review considers 
whether there is an association between severity of dis-
ease in patients with AD and the presence of an autoim-
mune response. From the papers identified using the search 
strategy, 16 papers evaluated the presence of autoimmunity 
in combination with disease severity. 13 papers provide 
evidence of the relationship between IgE autoantibodies 
and disease severity (Tables 5, 6), and two provide research 
relating to ANAs (Table 6). The final paper investigated 
ANAs, APL antibodies, and ACL antibodies and their rela-
tionship with severity (Table 6).
Two main methods of assessing severity were used, SCO-
RAD [44] and Rajka and Langeland [45] scores, although 
some researchers used other measures of severity. SCORAD 
was developed as a standardised method to assess sever-
ity of AD that could be used in outpatient clinics. It relies 
on three components: intensity (responsible for 60% of the 
total score), extent and subjective symptoms (each respon-
sible ≈ 20% of the score). Rajka and Langeland also put for-
ward a simple scoring index for AD using three parameters, 
each scored out of 3: extent, course (how much remission 
in a year) and intensity (scored according to how much it 
impacts sleep). The sum of these scores is calculated, with 
3–4 being defined as mild, 4.5–7.5 being moderate, and 8–9 
being severe.
It is difficult to produce pooled data for the studies 
assessing a link between IgE autoantibodies and severity 
of AD due to wide variation in the measures of sever-
ity and outcome measures but, as shown in Table 6; the 
weight of evidence indicates that there is an association 
between the frequency of IgE autoantibodies and disease 
severity in AD. Furthermore, two studies [48, 50] looked 
at individual patients over time, assessed levels of IgE 
autoantibodies and SCORAD throughout treatment, and 
established a temporal link between SCORAD and IgE 
autoantibodies. Whilst it is impossible to determine from 
these studies whether the decrease in IgE autoreactivity 
as severity of disease declines is a separate response to 
the cyclosporine A treatment, an unrelated biomarker 
resulting from a decrease in disease severity, or indeed 
the cause of the reduced severity, it provides strong sup-
port for a link between AD disease severity and autoim-
munity. This association did not seem to be present with 
respect to ANAs, as neither study that looked exclusively 
at ANAs demonstrated a significant association (Table 6), 
but more studies are required to reach a definitive conclu-
sion. Szakos et al. [34] also indicated that there was no 
significant difference in disease severity in patients that 
displayed ANAs, ACL, APL or a combination of ANAs 
and APL (Table 6). Overall, the available evidence indi-
cates that severity of AD is associated with autoimmunity, 
but that this response might be limited to IgE-mediated 
Fig. 3  Forest plot showing data from all studies into ANAs. ‘Events’ are instances of autoimmunity, ‘Total’ refers to the total number of people 
in that group of a study
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autoreactivity. However, further research is required into 
other indicators of autoimmunity, such as IgG autoanti-
bodies, ANAs and IgA autoantibodies to confirm this, as 
current evidence is limited in these areas.
Discussion
The weight of evidence presented in this review indicates 
that there is an association between autoreactivity and AD, 
as well as disease severity in AD, particularly with regard 
to autoantibodies of IgE class. However, this review cannot 
provide evidence for a causal link between the two, as the 
exact mechanisms for how autoimmunity occurs in patients 
with AD are unclear. Some papers hypothesise that cross 
reactivity between Malassezia spp. and the autoantigen 
hMnSOD could underlie the pathogenic response seen in 
AD [21, 25], whilst many others have identified cells in 
the skin as a source of autoantigens, potentially indicating 
that skin damage could lead to an autoimmune response 
to components within the skin, giving rise to autoimmun-
ity. However, these hypotheses rest on assumptions that 
have not been proven. Taking all the available evidence 
into account, it is not possible to declare that autoimmun-
ity is a pathogenic factor underlying the natural history 
of AD, but it does seem plausible and certainly worthy of 
future research.
This review points to several areas, where future 
research into autoimmunity and AD would be most valu-
able. First, some areas of autoimmunity have been less 
thoroughly investigated when looking at an association 
with AD. Whilst IgE autoantibodies and, to some extent, 
ANAs have been covered extensively by research, other 
markers of autoimmunity have less evidence available. 
Studies investigating IgG autoantibodies, for example, 
were varied in terms of control groups, often compar-
ing against groups that have other diseases, and were less 
clear about the selection criteria for the patients with AD. 
More research into IgG autoantibodies in AD, across a 
wide range of autoantigens and in comparison to healthy 
control groups, would be useful in drawing more robust 
conclusions.
Five other studies, not specifically covered by this 
review, have examined aspects of autoimmunity other than 
autoantibodies (Table 7). Collectively, these studies do 
indicate that autoimmunity is related to AD, with three of 
the five indicating statistically significantly higher rates 
of autoimmune response in patients with AD compared 
to their control groups, be it through increased histamine 
release upon stimulation by semi-purified sweat antigens 
[51], activation of iNKT cells without the corresponding 
ligand [52], or significantly higher stimulation index of 
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[47] show a greater frequency of response to intradermal 
injection of autologous sweat in AD patients, albeit with-
out statistical analysis. The final study [54] does not seem 
to indicate an increased autoreactive T-cell response in 
patients with AD, but does indicate that there may be an 
alteration to the balance of CLA+/CLA− and CCR4+/
CCR4− cells. Overall, these less traditional indicators of 
autoimmunity show promising results in terms of a link 
with AD, but further research is required to come to defini-
tive conclusions.
There are also new indicators of autoimmunity that, 
whilst not meeting the inclusion criteria of this review, 
could provide insight into AD. Some interesting papers 
have investigated the function of regulatory T cells 
(Tregs) in AD with research indicating that the sup-
pressive effect of Tregs on  CD8+CLA+ T-cell prolifer-
ation is inhibited in AD [55]. This would be a similar 
mechanism to other autoimmune/inflammatory diseases 
such as psoriasis, which shows impaired suppression of 
 CD4+CD25− T cells [56]. Zhang et al. [55] note that fur-
ther experiments are needed to address the theory that 
the  CD8+CLA+ T cells in patients with AD might resist 
suppression, as opposed to there being dysregulation of 
Tregs, but further research into this field could provide 
a valuable insight into the mechanism behind autoim-
munity. Later research corroborated this [57], with both 
papers suggesting that reduced inhibition of Teff cells 
could cause impaired self-tolerance in patients with AD, 
but further research would assist in elucidating specific 
mechanisms underlying the autoimmune response.
Another area that could provide useful research into 
autoimmunity and AD is analysis of genetic variants and 
potential associations with AD. For example, copy-number 
variations of the human histamine H4 receptor (HRH4) 
gene have been shown to be associated with AD [58], as 
well as a number of other autoimmune conditions such as 
SLE [59]. Whilst the exact mechanisms involved with the 
human histamine H4 receptor gene and AD are unclear, 
Chen et al. [58] suggest that the expression of HRH4 could 
be enhanced because of inflammatory stimuli found in 
autoimmune diseases, leading to a stronger response to 
histamine. This is an example of another potential com-
ponent to the autoimmune pathogenesis in AD and is an 
area that warrants future research.
How autoimmunity is related to AD in animal mod-
els also warrants further research. Using animal models 
could lead to greater understanding of whether autoim-
munity causes AD, perpetuates AD, or whether it is just 
an associated factor. Differences in ethical considera-
tions for humans and animals allows for different studies 
to be carried out in animals, allowing more flexibility 
in study design and an ability to more easily identify 
causation.
Finally, further research into how different pheno-
types of AD are associated with autoimmunity could 
provide a strong basis for future clinical research. 
Patients with AD can be divided into intrinsic and 
extrinsic categories, as well as other groups, including 
age of diagnosis and ethnic origin [60]. These groups 
have different disease characteristics, so more research 
into the underlying pathogenic mechanisms within these 
groups, be it related to autoimmunity or other factors, 
would be useful to aid understanding and potentially 
improve future treatments.
Table 6  Association of 
autoantibodies with severity of 
atopic dermatitis
*Differences were statistically significant
†Differences were not statistically significant
Marker of autoimmunity Papers that indicate a link between 
AD disease severity and autoim-
munity
Papers that do not indicate a link 
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Szakos et al., 2004 [34]
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